OncoSec Medical Stock

OncoSec Medical EBIT per Employee

Delisted

The EBIT per Employee of OncoSec Medical (ONCS) as of Aug 15, 2026 is -881,239.57 USD. In the previous year, EBIT per Employee was -1.15 M USD — a change of -23.50% (higher).

EBIT per Employee

-881,239.57USD

YoY

-23.50%

Last updated:

EBIT per Employee of OncoSec Medical is 2026 -881,239.57 USD. EBIT per Employee of OncoSec Medical was 2025 -1.15 M USD. It decreases by -23.50% higher compared to the previous year.
Access this data via the Eulerpool API

OncoSec Medical Stock analysis

What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OncoSec Medical stock

EBIT per Employee of OncoSec Medical is -881,239.57 USD in 2026.

EBIT per Employee of OncoSec Medical changed from -1.15 M USD to -881,239.57 USD, representing a -23.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's OncoSec Medical historically and in real time.

Access this data via the Eulerpool API

Workforce — OncoSec Medical

All Key Metrics — OncoSec Medical